Meyka Pro banner
LivaNova PLC

LivaNova PLC (NASDAQ: LIVN) Stock Competitors & Peer Comparison

See LIVN's competitors and their performance on the NASDAQ and across the wider stock market.

LIVNNASDAQ
HealthcareMedical - Devices
$82.20
$3.62(4.61%)
U.S. Market opens in 3h 55m

Peer Comparison Table: Medical - Devices Industry

Detailed financial metrics including price, market cap, P/E ratio, and more for LIVN and its NASDAQ peers.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
LIVN$82.20+4.61%4.4B19.19$4.21N/A
ABT$111.27+0.32%192.6B21.36$5.21+2.23%
BSX-PA$122.18+2.37%175.4B230.53$0.53N/A
SYK$341.09-1.76%130.8B25.47$13.39+1.02%
MDT$90.58-0.20%116B16.38$5.53+3.14%
BSX$51.69+0.53%76.9B16.68$3.10N/A
EW$92.56-0.53%53.3B34.29$2.70N/A
DXCM$91.48+0.75%34.5B39.26$2.33N/A
RMD$226.74+0.33%32.9B21.06$10.77+1.05%
PHG$27.38+2.16%26.8B15.64$1.75+3.62%
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

Abbott Laboratories (NYSE: ABT)

LIVN vs ABT Comparison August 2026

LivaNova PLC (NASDAQ: LIVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIVN stands at 4.4B. In comparison, ABT has a market cap of 192.6B. Regarding current trading prices, LIVN is priced at $82.20 on the NASDAQ, while ABT trades at $111.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIVN currently has a P/E ratio of 19.19, whereas ABT's P/E ratio is 21.36. In terms of profitability, LIVN's ROE is +0.15%, compared to ABT's ROE of +0.11%. Regarding short-term risk, LIVN is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for LIVN.Check ABT's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions